Literature DB >> 15108217

Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.

P Veng-Pedersen1, S Chapel, N H Al-Huniti, R L Schmidt, E M Sedars, R J Hohl, J A Widness.   

Abstract

OBJECTIVES: The objective was to study in vivo erythropoietin (Epo) progenitor cell surface receptors (EpoR) in the bone marrow (BM) after phlebotomy and bone marrow ablation.
METHODS: Serial tracer interaction method experiments were conducted in adult sheep at baseline and after phlebotomy (PH) and ablation (AB). PH was done 10 days after phlebotomy (to 3-4 g/dl Hb), and the AB was done 8 days after a 3-day oral treatment with bulsulfan (11 mg/kg/day).
RESULTS: Bone marrow ablation changed the elimination from non-linear to linear, consistent with an abolition of the non-linear elimination via BM EpoRs. The phlebotomy increased the linear clearance of the ablated elimination pathway (from 63.6+/-12 to 126+/-64 ml/h/kg), consistent with an up-regulation of the erythroid progenitor BM-based EpoR pool, but did not change the clearance of the non-ablated elimination pathway (p>0.05). The EpoR pool size remaining after BM ablation was 7.4+/-2.7% of the pre-ablation pool.
CONCLUSIONS: Erythropoietin elimination via EpoR in the bone marrow was non-linear and increased following phlebotomy-induced anemia. This is consistent with an up-regulation of the erythropoietic EpoR pool in BM. Assuming that the elimination of Epo after BM ablation was via non-hematopoietic EpoR, then this post-ablation EpoR population was not significantly up-regulated by the phlebotomy. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15108217     DOI: 10.1002/bdd.395

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  12 in total

1.  Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.

Authors:  Sihem Ait-Oudhia; Jean-Michel Scherrmann; Wojciech Krzyzanski
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

2.  Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects.

Authors:  Per Olsson-Gisleskog; Philippe Jacqmin; Juan Jose Perez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

4.  Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.

Authors:  Mohammed H El-Komy; Robert L Schmidt; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-06-15       Impact factor: 1.627

5.  Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.

Authors:  Mohammed H El-Komy; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-01-05       Impact factor: 3.922

6.  Multidose optimization simulation of erythropoietin treatment in preterm infants.

Authors:  Matthew R Rosebraugh; John A Widness; Peter Veng-Pedersen
Journal:  Pediatr Res       Date:  2012-02-15       Impact factor: 3.756

7.  Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.

Authors:  Mohammad I Saleh; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-01-10       Impact factor: 1.627

8.  Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.

Authors:  Matthew Rosebraugh; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-04-01       Impact factor: 3.922

9.  Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice.

Authors:  Anson K Abraham; Leonid Kagan; Sarmishtha Kumar; Donald E Mager
Journal:  J Pharmacol Exp Ther       Date:  2010-04-20       Impact factor: 4.030

10.  Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.

Authors:  Kevin J Freise; John A Widness; Jeffrey L Segar; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pharm Res       Date:  2007-04-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.